ストックスクリーナーアプリを入手
29.50
0.10%
-0.03
アフターアワーズ：
29.52
0.02
+0.07%
前日終値:
$29.53
開ける：
$28.89
24時間の取引高:
383.68K
Relative Volume:
5.04
時価総額：
$3.04B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$28.77
$30.26
1週間の範囲:
$25.06
$30.26
52週間の値動き範囲:
$25.06
$30.26
Metsera Inc Stock (MTSR) Company Profile
MTSR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
29.50 | 3.04B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metsera Inc (MTSR) 最新ニュース
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares - The Manila Times
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to - EIN News
Metsera shares leap on strong IPO performance By Investing.com - Investing.com Nigeria
Metsera shares leap on strong IPO performance - MSN
Metsera IPO opens 42% higher - MSN
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut - MSN
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut - Reuters
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 By Investing.com - Investing.com Australia
Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut - Smartkarma
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 - Investing.com
Metsera sees stock rally 54% following $275M IPO - MSN
Weight-loss drug developer Metsera raises $275 million in US IPO - MSN
Metsera sees stock rally 54% following $275M IPO (MTSR:NASDAQ) - Seeking Alpha
Metsera IPO opens 42% higher By Investing.com - Investing.com Nigeria
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut -January 31, 2025 at 01:02 pm EST - Marketscreener.com
Metsera Shares Rise Sharply in Nasdaq Debut -January 31, 2025 at 01:03 pm EST - Marketscreener.com
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon - MarketWatch
MTSR IPO NewsObesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - Renaissance Capital
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M - Fierce Biotech
Two more biotechs, Metsera and Maze, cross IPO finish line - pharmaphorum
Metsera and Maze Therapeutics Boost US Health Care IPOs to Record LevelsNews and Statistics - IndexBox, Inc.
Metsera Prices of Initial Public Offering - citybiz
Metsera, Maze raise a combined $415M in IPO double-header - FirstWord Pharma
Metsera, Maze secure combined $415 million in IPOs - BioPharma Dive
MTSRMetsera, Inc. Latest Stock News & Market Updates - StockTitan
Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut - Smartkarma
Metsera Readies $275 Million IPO For Obesity Treatments (Pending:MTSR) - Seeking Alpha
GLP-1RA developer Metsera targets $289m IPO - Pharmaceutical Technology
Three biotechs go public as IPO momentum increases - The Pharma Letter
Obesity drug developer Metsera sets terms for $275M IPO - MSN
Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs - Law360
Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation - Smartkarma
Metsera Seeks $289M Raise, $1.78B Valuation in IPO - BioSpace
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO - MSN
IPO excitement heats up as Metsera targets $1.8B valuation, Aurion joins queue - FirstWord Pharma
Metsera eyes $289M IPO to fund phase 3 weight loss trial - Fierce Biotech
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO - Yahoo Finance
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO - MSN
Metsera outlines $250M IPO plans as obesity biotech competition rises - Endpoints News
Weight-loss drug developer Metsera reveals wider loss in US IPO filing - MSN
Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech - Smartkarma
2024’s Top 7 VC Raises in Biotech - BioSpace
Obesity drug developer Metsera files for $100M IPO - MSN
Metsera Inc (MTSR) 財務データ
Metsera Inc (MTSR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Metsera Inc (MTSR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
1.09%
大文字化:
|
ボリューム (24 時間):